Sulfonamide

New US product, ORMALVI™ (dichlorphenamide) tablets, launches for Primary Periodic Paralysis (PPP) treatment

Retrieved on: 
수요일, 5월 8, 2024
FDA, General Health, Pharmaceutical, Health, Fetus, Cardiomyopathy, Torrent, Acidosis, Respiratory acidosis, Full, Diclofenamide, Risk, Pregnancy, Cognitive disorder, Milk, Aspirin, Metabolic acidosis, Dysgeusia, Hyperkalemia, Aplastic anemia, Partnership, PPP, Agranulocytosis, Anorexia nervosa, Human, Carbonic anhydrase inhibitor, SVP, Tablet, Incidence, Patient, Nursing, Lethargy, Serum, Hyperkalemic periodic paralysis, Diagnosis, Myopathy, Hypokalemic periodic paralysis, Paralysis, Paresthesia, Cycle, Stevens–Johnson syndrome, Hypokalemia, Quality of life, Argyreia nervosa, Sulfonamide, Coma, Pharmaceutical industry

We want to provide them with the support that they require to effectively manage their PPP.

Key Points: 
  • We want to provide them with the support that they require to effectively manage their PPP.
  • ORMALVI™ is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
  • Simply Stated: Research Updates in Periodic Paralysis - Quest | Muscular Dystrophy Association [online] Available at: https://mdaquest.org/simply-stated-research-updates-in-periodic-paralysis Accessed 23 Nov. 2023.
  • The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients.

Technology developed at The University of Tulsa and licensed by FortySix Venture Capital could advance cancer testing and targeted therapeutics

Retrieved on: 
화요일, 1월 10, 2023
Cancer, TU, Collins College, Invention, Research, University of Tulsa, Lamar, Oklahoma Center for the Advancement of Science and Technology, Sulfonamide, DRS, Faculty, Roger Hale Sheaffe, University, Therapy, Student, Chemistry, Biochemistry, Pharmaceutical industry, Management, Science

TULSA, Okla., Jan. 10, 2023 /PRNewswire/ -- FortySix Venture Capital LLC (46VC) and The University of Tulsa (TU) announced today that technology developed by TU researchers has been licensed by 46VC for commercialization efforts.

Key Points: 
  • TULSA, Okla., Jan. 10, 2023 /PRNewswire/ -- FortySix Venture Capital LLC (46VC) and The University of Tulsa (TU) announced today that technology developed by TU researchers has been licensed by 46VC for commercialization efforts.
  • Based on the teams' research, the technology licensed has the capability to radically change the time and expense required to target therapeutics for the deadliest forms of cancer.
  • 46VC and The University of Tulsa have executed a license arrangement that will accelerate the commercialization of these technologies.
  • The University of Tulsa and 46VC will begin working together to commercialize the important discovery immediately.

Animal Antibiotics and Antimicrobials Global Market to Reach $5.26 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
수요일, 9월 14, 2022
Pharmaceutical, Agriculture, Health, Natural Resources, Mode, Milk, Human, Diet, Asia-Pacific, Poultry, Meat, Acquisition, Bayer, Growth, Partnership, Industry, Egg, Tetracycline antibiotics, Solution, ADM, Research, PETS, Animal, Livestock, Aquaculture, Animal husbandry, Sulfonamide, Cephalosporin, Aminoglycoside, Elanco, Lincosamides, Macrolide, Penicillin, Injection, Quinolone antibiotic

The "Animal Antibiotics and Antimicrobials Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Animal Antibiotics and Antimicrobials Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • North America was the largest region in the animal antibiotics and antimicrobials market in 2021.
  • The regions covered in the animal antibiotics and antimicrobials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Rising demand for animal-derived food products is driving the growth of the animal antibiotics and antimicrobials market.

The Global Antibiotics Market Will Grow to USD 59,253.24 Million by 2028, at a CAGR of 3.76% - ResearchAndMarkets.com

Retrieved on: 
화요일, 3월 15, 2022
Health, General Health, Food and Drug Administration, Bacteria, D, AOM, Economy, Antibiotic sensitivity testing, Development, ASM, Society, Enterobacteriaceae, World, Ill, Geography, Infection, WHO, Bronchitis, Antibiotic, COVID-19, Macrolide, Upper respiratory tract infection, CAGR, Pathogenic bacteria, Pneumonia, Hospital, World Health Organization, Aminoglycoside, Organization, NCBI, Campylobacteriosis, Sulfonamide, 33, Meningitis, Food, Prevalence, Azerbaijan and Organization for Economic Co-operation, Sinusitis, Growth, Death, Diarrhea, Protein, RNA, UNICEF, Genetically modified bacteria, DNA, Poultry, Pharyngitis, Vaccine

The Antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 3.76% from 2020 to 2028.

Key Points: 
  • The Antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 3.76% from 2020 to 2028.
  • The growing prevalence of bacterial infection is one of the major factors increasing the demand for antibiotics globally.
  • Such potential increase in prevalence of bacterial infections is expected to continue to drive the growth of antibiotics market during the forecast period.
  • Based on drug class, the antibiotics market is segmented into sulfonamides, aminoglycosides, carbapenem, macrolides, fluoroquinolones, penicillin, cephalosporin, and others.

Global Acetic Anhydride Market Outlook to 2026: Focus on Tobacco, Pharmaceutical, Laundry & Cleaning, Agrochemical, & Textile Industries - ResearchAndMarkets.com

Retrieved on: 
화요일, 10월 19, 2021
Chemicals, Plastics, Manufacturing, Acquisition, BP, Sasol, JVS, INEOS, Textile, Eastman Chemical Company, Polymer, Medication, SABIC, Sulfonamide, Honeywell, USD, Industry, BASF, DuPont, BASF SE, Aspirin, SE, Commodity chemicals

The "Global Acetic Anhydride Market Outlook to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Acetic Anhydride Market Outlook to 2026" report has been added to ResearchAndMarkets.com's offering.
  • Global acetic anhydride market is expected to witness a significant growth rate during the forecast period.
  • The acetic anhydride market is mainly driven by massive demand from the cigarette tow market.
  • However, environmental regulations, coupled with the declining usage of acetic anhydride in cellulose acetate for domestic consumption, can significantly impact the market.

OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel

Retrieved on: 
월요일, 10월 4, 2021
Goal, Korea Disease Control and Prevention Agency, Securities Act of 1933, Lighthouse, Regulation of tobacco by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Carbapenem, Precision medicine, Death, University, Fungus, Pathology, LRT, Food, Aminoglycoside, Drug Quality and Security Act, Sulfonamide, CDC, Polymyxin, Infection, Gene, CEO, Knowledge, Penicillin, Technology, Nadine Opgen-Rhein, Antibiotic sensitivity testing, Solution, U.S. Securities and Exchange Commission, FDA, Hospital, Company, Science Publishing Group, Doctor of Philosophy, GLOBE, Adoption, NGS, Trimethoprim, Diagnosis, Security (finance), Patient, Cephalosporin, AMR, Bacteria, Antimicrobial stewardship, Medical laboratory, Center, COVID-19, Securities Exchange Act of 1934, Nasdaq, Vancomycin, Antibiotics, Vaccine

The Acuitas AMR Gene Panel detects 28 genetic antimicrobial resistance (AMR) markers in isolated bacterial colonies from 26 different pathogens.

Key Points: 
  • The Acuitas AMR Gene Panel detects 28 genetic antimicrobial resistance (AMR) markers in isolated bacterial colonies from 26 different pathogens.
  • Furthermore, we believe the Acuitas AMR Gene Panel is the first FDA cleared molecular diagnostic panel that detects such a broad panel of AMR markers from isolates.
  • The Acuitas AMR Gene Panel is the third molecular diagnostic panel that OpGen, as a group, has successfully received clearance for from the FDA, commented Johannes Bacher, Chief Operating Officer of OpGen.
  • This press release includes statements regarding OpGens Acuitas AMR Gene Panel for Isolates and clearance with the U.S. FDA.

BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada

Retrieved on: 
목요일, 9월 9, 2021

RALEIGH, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has completed the acquisition of U.S. and Canadian rights to ELYXYB™ (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited.

Key Points: 
  • ELYXYB is the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.
  • ELYXYBs unit-dose oral solution makes it convenient for patients to take it immediately upon emergence of acute migraine attacks.
  • BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.
  • ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.

Animal Antibiotics and Antimicrobials Market worth $5.6 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
월요일, 3월 8, 2021
Health sciences, Health, Articles, Antibiotic resistance, Pharmaceuticals policy, Veterinary medicine, Fluoroquinolone antibiotics, Quinolone antibiotic, Antimicrobial, Antibiotic, Ofloxacin, Sulfonamide

Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products.

Key Points: 
  • Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products.
  • In 2020, the premixes segment accounted for the largest share of 46.3% of the global animal antibiotics market.
  • Based on animal type, the global animal antimicrobials and antibiotics market is categorized into food-producing animals and companion animals.
  • The animal antimicrobials and antibiotics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Animal Antibiotics and Antimicrobials Market worth $5.6 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
월요일, 3월 8, 2021
Health sciences, Health, Articles, Antibiotic resistance, Pharmaceuticals policy, Veterinary medicine, Fluoroquinolone antibiotics, Quinolone antibiotic, Antimicrobial, Antibiotic, Ofloxacin, Sulfonamide

Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products.

Key Points: 
  • Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products.
  • In 2020, the premixes segment accounted for the largest share of 46.3% of the global animal antibiotics market.
  • Based on animal type, the global animal antimicrobials and antibiotics market is categorized into food-producing animals and companion animals.
  • The animal antimicrobials and antibiotics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Premier Inc. ProvideGx® Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole/Trimethoprim

Retrieved on: 
화요일, 8월 4, 2020
Supply chain management, Professional services, Retail, Health, Hospitals, Consulting, Pharmaceutical, Chemical compounds, Drugs, RTT, Aromatic amines, Aromatic compounds, Sulfameth, Trimethoprim, Sulfonamide, Urinary tract infection

(NASDAQ: PINC), through its ProvideGx program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory infections, a common complication associated with COVID-19.

Key Points: 
  • (NASDAQ: PINC), through its ProvideGx program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory infections, a common complication associated with COVID-19.
  • Somerset is a new market entrant for this drug, working to creating a viable, competitive alternative and second source of supply.
  • At the same time, this deal provides a long-term contract to Somerset, creating predictable demand for years into the future.
  • Together with privately owned, U.S.-based Somerset Therapeutics, established in 2015, Somerset develops, manufactures and markets generic injectable and ophthalmic drugs.